Mesoblast set for Asian launch
Monday, 16 February, 2009
Melbourne biotech Mesoblast has signed a collaborative program with Singapore’s Parkway Group Healthcare to trial its cartilage stem cell product RepliCart.
RepliCart is aimed at preventing or treating osteoarthritis of the knee, both in the elderly and following knee reconstruction surgery.
Last month, Mesoblast announced it was beginning Phase II trials of RepliCart in people under 40 who had undergone anterior cruciate ligament surgery
The agreement with Parkway Group Healthcare, which operates 15 private hospitals in Asia, involves a single-injection safety and efficacy trial at Parkway’s Clinical Centre of Excellence in Singapore.
Mesoblast said further trials were planned for additional clinical indications.
Inhaled form of blood thinner treats serious COVID infections
Heparin has traditionally been injected and used to treat blood clots, but the new study tested...
Next-gen therapies could treat high-grade gliomas
Government funding will enable researchers to test a suite of next-generation therapies they have...
Bacteriophage cocktail to combat superbugs
Entelli-02 is a five-phage cocktail designed specifically to target Enterobacter cloacae...
